Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
SLC5A2 6524 TOFOGLIFLOZIN HYDRATE CHEMBL2105711 inhibitor ChemblInteractions
SLC5A2 6524 CHEMBL2018096 CHEMBL2018096 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions
SLC5A2 6524 SERGLIFLOZIN ETABONATE CHEMBL450044 inhibitor GuideToPharmacologyInteractions
SLC5A2 6524 DAPAGLIFLOZIN PROPANEDIOL CHEMBL2103802 inhibitor ChemblInteractions
SLC5A2 6524 BEXAGLIFLOZIN CHEMBL1808388 inhibitor ChemblInteractions
SLC5A2 6524 REMOGLIFLOZIN CHEMBL494322 inhibitor GuideToPharmacologyInteractions
SLC5A2 6524 SOTAGLIFLOZIN CHEMBL3039507 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
SLC5A2 6524 GLUFOSFAMIDE CHEMBL2107143 TdgClinicalTrial
SLC5A2 6524 CANAGLIFLOZIN HYDRATE CHEMBL2103841 inhibitor ChemblInteractions
SLC5A2 6524 OXYBATE CHEMBL1342 TdgClinicalTrial
SLC5A2 6524 ERTUGLIFLOZIN CHEMBL1770248 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
SLC5A2 6524 TOFOGLIFLOZIN CHEMBL2110731 inhibitor GuideToPharmacologyInteractions
SLC5A2 6524 REMOGLIFLOZIN ETABONATE CHEMBL2028665 inhibitor, blocker ChemblInteractions, TTD
SLC5A2 6524 CANAGLIFLOZIN CHEMBL2048484 inhibitor, blocker TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 23590413
SLC5A2 6524 EMPAGLIFLOZIN CHEMBL2107830 antagonist, inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 25598831
SLC5A2 6524 DAPAGLIFLOZIN CHEMBL429910 antagonist, inhibitor, blocker, inhibitor, competitive TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 19996149

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
SLC5A2 rs3116149 A empagliflozin efficacy no No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed. Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G. 28134748 1448603685
SLC5A2 rs3813008 A empagliflozin efficacy no No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed. Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G. 28134748 1448603703
SLC5A2 rs9924771 A empagliflozin efficacy no No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed. Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G. 28134748 1448603665
SLC5A2 rs11646054 C empagliflozin efficacy no No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed. Allele C is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G. 28134748 1448603676
SLC5A2 rs3116150 A empagliflozin efficacy no No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed. Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G. 28134748 1448603694